OMERO PLUS
LIVE

Serial Number

79325753

Owner

Glencoe Software Inc.

Attorney

Stacey J. Watson

Filing Date

Aug 31, 2021

Add to watchlist:

No watchlists yet
View on USPTO

OMERO PLUS Trademark

Serial Number: 79325753 • Registration: 7497634

OMERO PLUS is a trademark filed by Glencoe Software Inc. on August 31, 2021. The trademark is classified under Class 9 (Computers & Electronics), Class 42 (Computer & Scientific), Class 45 (Legal & Security Services), Class 35 (Advertising & Business). The application is currently registered and active.

Owner Contact Info

Glencoe Software Inc. (13 trademarks)

800 5th Avenue #101-259

Entity Type: 03

Trademark Details

Filing Date

August 31, 2021

Registration Date

September 10, 2024

Published for Opposition

November 29, 2022

Goods & Services

Downloadable computer software that is downloaded and installed for use in connection with the accessing, visualisation, analysis, management, publication, sharing, storage and manipulation of biological and biomedical data and images in the field of healthcare, life science and biomedical science; downloadable computer software that is downloaded and installed from the Internet for use in connection with the accessing, visualisation, analysis, management, publication, sharing, storage and manipulation of biological and biomedical data and images in the field of healthcare, life science and biomedical science; downloadable data access and data management software tools that are downloaded and installed for use in connection with the accessing, visualisation, analysis, management, publication, sharing, storage and manipulation of biological and biomedical data and images in the field of healthcare, life science and biomedical science; downloadable electronic publications in the nature of scientific journals, periodicals and newsletters relating to the accessing, visualisation, analysis, management, publication, sharing, storage and manipulation of biological and biomedical data and images in the field of healthcare, life science and biomedical science; none of the foregoing for use by clinical care providers, future or current patients, or their families in connection with pharmaceuticals, biopharmaceuticals or therapeutic methods, or produced, designed, or marketed for providing medical and scientific research summaries, reports, or opinions regarding the efficacy, safety, pharmacological characteristics, or other properties of pharmaceutical and biopharmaceutical products, product candidates, development programs, therapeutic methods, drug delivery systems, medical treatments, or diagnostic methods, and relating to a specific disease, disorder, or category thereof.

Business services relating to the accessing, visualisation, analysis, management, publication, sharing, storage and manipulation of biological and biomedical data and images in the field of healthcare, life science and biomedical science, namely, management of biological and biomedical data and images for business enterprises; data processing services relating to the accessing, visualisation, analysis, management, publication, sharing, storage and manipulation of biological and biomedical data and images in the field of healthcare, life science and biomedical science; information, advisory and consultancy services in connection with the aforesaid services; none of the foregoing for use by clinical care providers, future or current patients, or their families in connection with pharmaceuticals, biopharmaceuticals or therapeutic methods, or produced, designed, or marketed for providing medical and scientific research summaries, reports, or opinions regarding the efficacy, safety, pharmacological characteristics, or other properties of pharmaceutical and biopharmaceutical products, product candidates, development programs, therapeutic methods, drug delivery systems, medical treatments, or diagnostic methods, and relating to a specific disease, disorder, or category thereof.

Licensing of computer software for use in connection with the accessing, visualisation, analysis, management, publication, sharing, storage and manipulation of biological and biomedical data and images in the field of healthcare, life science and biomedical science; information, advisory and consultancy services in connection with the aforesaid services; none of the foregoing for use by clinical care providers, future or current patients, or their families in connection with pharmaceuticals, biopharmaceuticals or therapeutic methods, or produced, designed, or marketed for providing medical and scientific research summaries, reports, or opinions regarding the efficacy, safety, pharmacological characteristics, or other properties of pharmaceutical and biopharmaceutical products, product candidates, development programs, therapeutic methods, drug delivery systems, medical treatments, or diagnostic methods, and relating to a specific disease, disorder, or category thereof.

Design and development of computer software, data access and data management software tools for use in connection with the accessing, visualisation, analysis, management, publication, sharing, storage and manipulation of biological and biomedical data and images in the field of healthcare, life science and biomedical science; computer programming; installation, maintenance and repair of computer software; design of computer websites and maintenance thereof, all relating to the accessing, visualisation, analysis, management, publication, sharing, storage and manipulation of biological and biomedical data and images in the field of healthcare, life science and biomedical science; software as a service (SaaS) featuring software for accessing, visualisation, analysis, management, publication, sharing, storage and manipulation of biological and biomedical data and images in the field of healthcare, life science and biomedical science; information, advisory and consultancy services in connection with the aforesaid services; none of the foregoing for use by clinical care providers, future or current patients, or their families in connection with pharmaceuticals, biopharmaceuticals or therapeutic methods, or produced, designed, or marketed for providing medical and scientific research summaries, reports, or opinions regarding the efficacy, safety, pharmacological characteristics, or other properties of pharmaceutical and biopharmaceutical products, product candidates, development programs, therapeutic methods, drug delivery systems, medical treatments, or diagnostic methods, and relating to a specific disease, disorder, or category thereof.

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
Apr 26, 2025 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Apr 4, 2025 FICS
FINAL DISPOSITION PROCESSED
Apr 4, 2025 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Dec 10, 2024 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Sep 10, 2024 NRCC
REGISTERED-PRINCIPAL REGISTER
Sep 10, 2024 R.PR
TTAB RELEASE CASE TO TRADEMARKS
Aug 7, 2024 TMBN
OPPOSITION TERMINATED NO. 999999
Aug 7, 2024 OP.T
OPPOSITION DISMISSED NO. 999999
Aug 7, 2024 OP.D
REFUSAL PROCESSED BY IB
Jun 26, 2023 RFNT
OPPOSITION INSTITUTED NO. 999999
Jun 1, 2023 OP.I
OPPOSITION NOTICE (IB REFUSAL) SENT TO IB
May 29, 2023 OPNS
OPPOSITION NOTICE (IB REFUSAL) CREATED
May 27, 2023 OPNC
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
May 9, 2023 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Apr 19, 2023 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Apr 19, 2023 OPNR
NOTIFICATION PROCESSED BY IB
Dec 12, 2022 GPNX
EXTENSION OF TIME TO OPPOSE RECEIVED
Nov 30, 2022 ETOF
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Nov 29, 2022 NPUB
PUBLISHED FOR OPPOSITION
Nov 29, 2022 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Nov 23, 2022 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Nov 23, 2022 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 9, 2022 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 26, 2022 CNSA
EXAMINER'S AMENDMENT ENTERED
Oct 26, 2022 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Oct 26, 2022 GNEN
EXAMINERS AMENDMENT E-MAILED
Oct 26, 2022 GNEA
EXAMINERS AMENDMENT -WRITTEN
Oct 26, 2022 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 20, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 19, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 19, 2022 TROA
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Oct 5, 2022 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Oct 5, 2022 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Oct 5, 2022 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Oct 5, 2022 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Oct 5, 2022 COAR
REFUSAL PROCESSED BY IB
Jul 19, 2022 RFNP
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jun 28, 2022 RFCS
REFUSAL PROCESSED BY MPU
Jun 27, 2022 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jun 10, 2022 RFCR
NON-FINAL ACTION WRITTEN
Jun 9, 2022 CNRT
ASSIGNED TO EXAMINER
Jun 6, 2022 DOCK
APPLICATION FILING RECEIPT MAILED
Dec 10, 2021 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Dec 6, 2021 NWOS
LIMITATION FROM ORIGINAL APPLICATION ENTERED
Dec 2, 2021 LIMI
SN ASSIGNED FOR SECT 66A APPL FROM IB
Nov 18, 2021 REPR